<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Neostigmine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01400</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01400/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01400/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01400.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01400.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01400.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01400.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01400.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01400">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Eustigmin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Eustigmine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>m-Trimethylammoniumphenyldimethylcarbamate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Neostigmine methylsulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000128/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000128/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OSZNNLWOYWAHSS-UHFFFAOYSA-M</li>
              <li>Monoisotopic Mass: 334.119857136</li>
              <li>Average Mass: 334.389</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000128">DBSALT000128</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bloxiverz</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prostigmin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vagostigmin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>59-99-4</td></tr><tr><th>Weight</th><td>Average: 223.2915<br>Monoisotopic: 223.144652862</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>ALWKGYPQUAPLQC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Ethers</td></tr><tr><th>Direct parent</th><td>Phenol Ethers</td></tr><tr><th>Alternative parents</th><td>Tertiary Amines; Carbamic Acids and Derivatives; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>carbamic acid derivative; tertiary amine; ether; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.</td></tr><tr><th>Pharmacodynamics</th><td>Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.

</td></tr><tr><th>Mechanism of action</th><td>Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.</td></tr><tr><th>Absorption</th><td>Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Protein binding to human serum albumin ranges from 15 to 25 percent.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 &#177; 0.02 mg/kg intravenously, 0.54 &#177; 0.03 mg/kg subcutaneously, and 0.395 &#177; 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 &#177; 0.019 mg/kg intravenously, 0.445 &#177; 0.032 mg/kg subcutaneously, and 0.423 &#177; 0.032 mg/kg intramuscularly.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8576</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9583</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.608</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8263</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9598</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9279</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9181</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7197</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6869</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.622</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9367</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9424</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8362</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5146
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5931
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7893
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9481 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.952
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8738
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.pharmedium.com">Pharmedium</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intramuscular</td><td></td></tr><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>